ProMIS reports PMN310 oligomer reduction at 29 days
ProMIS Neurosciences (NASDAQ:PMN) reported first human evidence that PMN310 reduced detectable amyloid-beta oligomers in cerebrospinal fluid dose-dependently at days three and 29, providing an exploratory signal that the antibody reached and engaged its intended target.










